Videos

The chief medical officer of New England Center for Neurology and Headache talked about trends observed in the clinical practice with Daxxify, a long-acting botulinum toxin for patients with cervical dystonia. [WATCH TIME: 5 minutes]

Key opinion leaders emphasize the importance of neuroimaging in Alzheimer's disease, as it can rule out different diseases and diagnose microbleeds, while also discussing which biomarkers, histopathological features, and imaging characteristics are associated with different stages of the disease, exploring whether these tools can provide insights into the true onset of Alzheimer's disease.

Sharon Cohen, MD, and Marwan Sabbagh, MD, discuss the current understanding of tau as a marker of neuronal injury and its role in the pathophysiology of Alzheimer's disease, particularly focusing on the significance of phosphorylated tau and neurofibrillary tangles in the disease process.

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, share perspectives on the future of MS care, the importance of vigilance in lab testing, and why patients may need reassurance about the potential for disease control with currently available therapies.

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, discuss the need for biomarkers that can help guide the optimal dosing for the use of anti-CD20 therapies in a precision fashion.

The associate professor of neurology at Harvard Medical School discussed how clinicians face the challenging decision with their patients in choosing between off-label and approved medications for NMOSD. [WATCH TIME: 4 minutes]

Neurology News Network. for the week ending May 18, 2024. [WATCH TIME: 4 minutes]

Drs Thorpy, Dogan, Doghramji, and Kushida share clinical pearls for primary care providers who are taking care of patients with narcolepsy.

Experts in sleep medicine the ongoing studies and new treatments for narcolepsy

Drs Thorpy, Dogan, Doghramji, and Kushida talk about treatment holidays in narcolepsy.

The associate professor in the department of radiology at NYU Langone provided perspective on the unanswered questions regarding neuronal microstructure in migraine following her presentation at the 2024 AAN Annual Meeting. [WATCH TIME: 4 minutes]

The associate professor of neurology at Harvard Medical School talked about findings from a recent case series of patients with NMOSD initially on rituximab who then switched to inebilizumab. [WATCH TIME: 4 minutes]

The Consortium of Multiple Sclerosis Centers' 38th Annual Meeting will be held Wednesday, May 29, through Saturday, June 1, 2024 at the Music City Center, in Nashville, Tennessee.

The professor of neurological surgery at Weill Cornell medicine talked about how gene therapy may offer a more direct and efficient pathway to develop treatments for neurological diseases like Parkinson disease. [WATCH TIME: 6 minutes]

The director of the Brain Health Imaging Institute in the department of radiology at Weill Cornell Medicine talked about exploring nasal pathways as an alternative for brain protein sampling and drug delivery. [WATCH TIME: 4 minutes]

The professor of neurological surgery at Weill Cornell medicine talked about the regulatory hurdles and challenges in patient selection and delivery methods for gene therapy in Parkinson disease. [WATCH TIME: 5 minutes]

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, discuss the utility of real-world data, particularly when it comes to understanding subtle differences between agents from both a safety and efficacy perspective.

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, discuss emerging the practical implications of long-term data for anti-CD20 agents.

The head of neurosciences at the Jane and John Justin Neurosciences Center of Cook Children’s Medical Center detailed some of consequences of undiagnosed or misdiagnosed LGS, and how it may impact long-term care for eligible patients. [WATCH TIME: 4 minutes]

Panelists delve into the amyloid cascade hypothesis of Alzheimer's disease and the ongoing debate surrounding it, discussing the presence and potential roles of Aβ monomers, oligomers, protofibrils, and amyloid plaques in patients with Alzheimer's disease.

The panel provides an overview of amyloid precursor protein (APP) and the generation of amyloid β (Aβ) peptides, Aβ42 and Aβ40, while also discussing which soluble or insoluble Aβ species (monomers, oligomers, protofibrils, or amyloid plaques) contribute to neuronal damage and the clinical manifestation of Alzheimer's disease.

The director of Dysautonomia Clinic talked about advocating for recognition and research into neurological symptoms that have long been overlooked in patients with Long COVID. [WATCH TIME: 3 minutes]

Neurology News Network. for the week ending May 11, 2024. [WATCH TIME: 4 minutes]

The director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester discussed treatment response and safety findings from the phase 3 ACCORD study assessing AXS-05 for agitation in Alzheimer disease. [WATCH TIME: 6 minutes]

Sleep medicine experts review when to consider switching treatment in narcolepsy.

Experts in sleep medicine discuss the criteria for changing treatment in narcolepsy.

Kremens gave closing thoughts on the promise of the Parkinson disease research field, the outlook of drug development, and what clinicians should be excited for next.

Daniel Kremens, MD, JD, described positive 18-month data on bemdaneprocel, an investigational cell-based approach for patients with Parkinson disease.

The neurologist at Mass General Hospital discussed adopting AI technologies in neurology practice, emphasizing the importance of addressing equity concerns alongside technological advancements. [WATCH TIME: 5 minutes]

The director of the PET Imaging Program in Neurologic Diseases at Brigham and Women’s Hospital talked about nasal administration of foralumab that shows promise in treating patients with non-active secondary progressive MS. [WATCH TIME: 5 minutes]